Skip to main content

Table 2 Univariate Cox proportional hazards ratios and 95% confidence intervals in univariate analyses for association between EndoPredict, clinicopathological variables and metastasis-free survival

From: Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial

Variables HR (95% CIa) P-value
EP 1.207 (1.134 to 1.285) <0.0001
EPclin 1.916 (1.625 to 2.259) <0.0001
Age 0.977 (0.960 to 0.993) 0.0065
Tumor size   0.0159b
  ≤1 Reference value  
  >1 to ≤2 cm 1.038 (0.457 to 2.357) 0.9290
  >2 to ≤5 cm 1.919 (0.884 to 4.168) 0.0994
  >5 cm 2.102 (0.762 to 5.798) 0.1511
Number of positive nodes   <0.0001b
  1 to 3 Reference value  
  4 to 10 1.631 (1.085 to 2.451) 0.0187
  >10 4.911 (3.022 to 7.979) <0.0001
Grade   0.0233b
  G1 Reference value  
  G2 2.263 (1.157 to 4.428) 0.0171
  G3 2.883 (1.446 to 5.746) 0.0026
  Unknown 1.844 (0.749 to 4.538) 0.1829
Treatment arm   0.6067b
  FEC Reference value  
  FEC-P 0.910 (0.635 to 1.304)  
ER (Allred score c ) 0.950 (0.886 to 1.019) 0.1505
PR (Allred score c ) 0.923 (0.874 to 0.974) 0.0033
Ki67 (quantitative) 1.017 (1.004 to 1.030) 0.0080
  1. aEP: EndoPredict; EPclin: Combined molecular and clinical score; CI: Confidence interval; ER: Estrogen receptor; HR: Hazard ratio; MFS: Metastasis-free survival; PR: Progesterone receptor. Number of patients included in the analyses is 555. bP-value of the variable’s overall effect on MFS. cAllred et al. [18].